Literature DB >> 709890

Acute endocrine profile of sulpiride in the human.

M L'Hermite, P Denayer, J Golstein, E Virasoro, L Vanhaelst, G Copinschi, C Robyn.   

Abstract

Normal men and normally menstruating women received i.m. injections of 0.1 to 4.0 mg/kg sulpiride. This psychotropic drug induced a very rapid (already significant after 5 minutes) and sustained (still significant after 7 hours) elevation of prolactin (PRL) concentrations in all subjects with no consistent modification of LH and FSH. After injection of 4.0 mg/kg, there was similarly no modification of mean TSH concentrations in the women tested in the luteal phase, as well as of mean GH levels in men. Sulpiride prevented the inhibitory effect on PRL levels of 500 mg levodopa, administered orally simultaneously; levodopa administered 2 hours prior to sulpiride failed to counteract the PRL-stimulatory effect of sulpiride. Under chronic sulpiride-induced hyperprolactinaemia, levodopa exhibited however a very slight inhibitory effect on PRL concentrations. These data are in agreement with the hypothesis that sulpiride acts mainly at the pituitary level by blocking dopamine receptors of the lactotropes and support the concept that the menstrual cycle perturbations observed under chronic sulpiride administration result from hyperprolactinaemia itself or from a mechanism quite similar to that by which sulpiride induces hyperprolactinaemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 709890     DOI: 10.1111/j.1365-2265.1978.tb02200.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

2.  Influence of the dosing interval on prolactin release after remoxipride.

Authors:  G Movin-Osswald; M Hammarlund-Udenaes; C Von Bahr; P Eneroth; K Walton-Bowen
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

3.  Prolactin unresponsiveness to repeated sulpiride administration in man: recent findings.

Authors:  G P Bernini; M Gasperi; G Gravina; M S Vivaldi; C Del Corso; R Santoni; M Luisi; F Franchi
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

4.  Possible mechanism of prolactin unresponsiveness to repeated sulpiride administration in man.

Authors:  G P Bernini; M Gasperi; M S Vivaldi; R Santoni; M Luisi; F Franchi
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Dose-related effects of gamma-amino beta-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women.

Authors:  G B Melis; A M Paoletti; V Mais; N M Mastrapasqua; F Strigini; F Fruzzetti; G Guarnieri; M Gambacciani; P Fioretti
Journal:  J Endocrinol Invest       Date:  1982 Mar-Apr       Impact factor: 4.256

6.  Unresponsiveness of prolactin to repeated injection of sulpiride in man.

Authors:  H Cohen; M Pugeat; J Tourniaire; J Bertrand
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.